Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing

Figure 1

Overview of patients with cancer enrolled in the study and the proportions of fibroblast growth factor receptor 2 (FGFR2) genetic alterations. Between December 2019 and January 2021, patients with stage IV cancer were screened for FGFR2 aberrations via next-generation sequencing using a panel that targeted 500+ genes in the Gastrointestinal/Genitourinary/Rare Cancer/Phase I Oncology Clinic of Samsung Medical Center. A Venn diagram indicating the (a) percentage of each type of cancer in a total of 1,373 patients and the (b) percentage of cases with FGFR2 amplification, FGFR2 fusion, or the cooccurrence of FGFR2 amplification and fusion is shown. (c) A summary table showing the tumor types and numbers of patients is shown. AOV: ampulla of vater; CBD: common bile duct; HCC: hepatocellular carcinoma; MUO: metastasis of unknown origin; GIST: gastrointestinal stromal tumor.